Abstract 233P
Background
Health is a state of complete wellbeing free from any discomfort and pain. Despite remarkable world-wide progress in the field of diagnostic, curative and preventive medicine, still there are large populations of people living in isolation in natural and unpolluted surroundings far away from civilisation, maintaining their traditional values, customs, beliefs and myths. India has the second largest tribal population of the world next to the African countries. The present study was conducted to assess the cancer awareness, tobacco use, and its effect on health among Malayali tribes, Yelagiri Hills, Tamil Nadu, India.
Methods
After a study among this population of 660 in 2010, extended research was carried out in 2018 among 2185 participants. The inhabitants of the 14 villages of the Yelagiri Hills, who were willing to participate in the study were included. Data was collected from a cross-sectional survey, using a survey proforma, clinical examination and a pre-tested questionnaire which included demographic data, tobacco habits. A brief tobacco cessation counseling was given to all the users. SPSS version 21 was used for statistical analysis.
Results
The study showed that among the 2185 study population, 47% had no formal education. Of those who had the habit of smoking, 29% smoked beedi, 31% smoked cigarettes, 39% chewed raw tobacco, 33% chewed Hans, and 12% had a combination of smoking and smokeless tobacco usage. Prevalence of oral mucosal lesions 47% and 7% oral cancer in the study population was due to tobacco usage and lack of awareness regarding the deleterious effects of the products used.
Conclusions
From the results of this study it may be concluded that the Malayali tribes were characterized by a lack of awareness about oral health, deep rooted dental beliefs, high prevalence of tobacco use and limited access to health services.
Clinical trial identification
Editorial acknowledgement
NA
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract